The Lancet
Study
May 2002
Patients and professionals
This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.
Topics
Biologics and newer medicines
Research
Jargon explained
maintenance therapy
remission
placebo
New England Journal of Medicine
Study
Feb 2004
Patients and professionals
A trial in people with Crohn's fistulas (abnormal tunnels, often around the anus) who had responded to infliximab. Carrying on with infliximab every 8 weeks kept people well for much longer than switching to a dummy drug. At one year, 36% on infliximab had no draining fistulas, against 19% on placebo.
Topics
Around the bottom (perianal)
Biologics and newer medicines
Jargon explained
fistula
fistulizing disease
placebo
Gastroenterology
Study
Jan 2007
Patients and professionals
The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.
Topics
Biologics and newer medicines
Jargon explained
maintenance
remission
CDAI
placebo
New England Journal of Medicine
Study
Nov 2016
Patients and professionals
The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.
Topics
Biologics and newer medicines
Jargon explained
induction
maintenance
IL-12/23
placebo
Cochrane
Systematic review
Oct 2015
Patients and professionals
Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.
Topics
Immunosuppressants
Research
Jargon explained
thiopurine
low-quality evidence
adverse event
remission
placebo
systematic review
The Lancet
Study
May 2022
For professionals
The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.
Topics
Biologics and newer medicines
Research
Jargon explained
IL-23
maintenance
placebo
endoscopic response
Cochrane (via PMC)
Systematic review
Nov 2019
Patients and professionals
A Cochrane review with high-certainty evidence that adalimumab works better than placebo for bringing moderate to severe Crohn's into remission. Long-term safety needed more study.
Topics
Biologics and newer medicines
Research
Jargon explained
induction
placebo
anti-TNF
Cochrane
Systematic review
Nov 2021
Patients and professionals
Tummy pain often continues in Crohn's even when inflammation is under control. This review looked for treatments aimed at the pain itself but found so few, small studies that no conclusions could be drawn.
Topics
Pain
Research
Jargon explained
abdominal pain
sham
remission
stricture
adhesions
low fodmap diet
Crohn's & Colitis UK
Guide
Dec 2025
For patients
A detailed guide to the tests used to diagnose and monitor Crohn's and colitis: blood tests (full blood count, CRP, liver and kidney tests), poo tests including faecal calprotectin and FIT, endoscopies with tips on bowel prep, capsule endoscopy and the dummy patency capsule, and X-rays, CT, MRI and ultrasound. It explains what results can and cannot tell you, for example that calprotectin can be normal during a flare in the small bowel.
Topics
Diagnosis and tests
Monitoring
Jargon explained
full blood count
C-reactive protein
faecal calprotectin
faecal immunochemical test
colonoscopy
gastroscopy
capsule endoscopy
patency capsule
biopsy
bowel preparation
New England Journal of Medicine
Study
May 2023
Patients and professionals
Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.
Topics
Medicines
Immunosuppressants
Research
Jargon explained
JAK inhibitor
small molecule
induction
maintenance
herpes zoster
endoscopic response
New England Journal of Medicine
Study
Aug 2013
Patients and professionals
The main trial of vedolizumab (Entyvio) in Crohn's. It helped more people reach remission than placebo by week 6, and people who responded and stayed on it were more likely to be in remission at one year. Side effects, including infections, were somewhat more common than on placebo in this trial.
Topics
Biologics and newer medicines
Jargon explained
integrin
induction
maintenance
serious adverse event
Cochrane
Systematic review
Jul 2016
Patients and professionals
Mesalazine-type drugs (aminosalicylates) are widely used for ulcerative colitis, but this review found little evidence that they work for active Crohn's. Low and high doses of mesalazine were not clearly better than placebo. Some trials comparing high-dose mesalazine with budesonide gave mixed results.
Topics
Medicines
Jargon explained
aminosalicylate
5-ASA
mesalazine